Subject Index

- A**
- Accessory limb model (ALM), 587
- Acute lymphoblastic leukemias (ALL)
- modeling of Ph⁺ ALL in the mouse, 463–464
 - resistance to targeted therapy in Ph⁺ ALL, 464–466
- Acute myelogenous leukemia (AML), 442
- Adult stage stem cell self-renewal
- differences relative to fetal stem cells, 543
 - germ-line, 543
 - hematopoietic, 543–544
 - neural, 544–545
- Adult stem cell lineages
- in the brain (*see* Neural stem/progenitor cells [NSCs])
 - in *Drosophila* (*see* *Drosophila*, male GSC lineages)
 - expression of terminal differentiation genes, 143
 - key regulatory points, 137–138
 - research and future directions, 143–144
- Affinophoresis, 588
- Aging stem cell self-renewal
- hematopoietic, 545
 - insights from other systems, 546–548
 - neural, 546
 - stem cells/niche interactions and, 43
- AGM (aorta-gonad-mesonephros), 112
- Akt* regulation, 515, 517, 519
- Alb1* locus, 120–121, 122–124
- ALL (acute lymphoblastic leukemias)
- modeling of Ph⁺ ALL in the mouse, 463–464
 - resistance to targeted therapy in Ph⁺ ALL, 464–466
- ALM (accessory limb model), 587
- AML (acute myelogenous leukemia), 442
- Amyotrophic lateral sclerosis (ALS), 404
- Androgen receptor (AR), 530
- Aorta-gonad-mesonephros (AGM), 112
- Arabidopsis thaliana*
- analysis of state transitions in, 239–240
 - heterochromatic silencing in, 266–269
 - homeostasis regulation in, 246
 - stem cell system described, 238–239
- Argonaute/Piwi proteins and piRNAs, 273–274
- Astrocytomas
- background to research, 421
 - cancer stem cells in mouse models, 423, 425
 - mouse model of malignant, 422
 - Notch pathways in, 371–372
 - role of NSCs in development of malignant, 423, 424
 - stem cells in the brain and, 421–422
 - study conclusions and perspectives, 425
 - tumor suppressor mouse models, 422–423
- tumor suppressor pathways and, 422
- Asymmetric cell division
- of clonally selected T cells, 76–77
 - lymphocytes and, 75
 - possibility of in blood lineages, 77
 - stem cell research and, 596–597
 - in yeast
 - asymmetric segregation of kinetochore proteins, 82–84
 - asymmetry of spindle pole body segregation, 84
 - histone *HTA1* segregation, 82
 - lack of evidence of immortal strands in yeast, 86–87
 - segregating immortal DNA strands, 84–85
 - selective centromere segregation, 87
 - study conclusions, 87
 - study overview, 81
 - testing the immortal strand hypothesis, 85–86
 - tracking nonencoded protein, 82
- B**
- BASCs (bronchioalveolar stem cells), 479. *See also* Lung stem cell biology
- β -catenin in epidermal stem cells. *See also* Skin stem cells
- approaches to identifying and manipulating, 504
 - background, 503–504
 - β -catenin/Tcf/Lef complex, 508–509
 - in cultured keratinocytes, 505–506
 - K14 promoter/ β -catenin model, 506, 507, 508, 510
 - in mouse epidermis, 506–507
 - pathways that induce stem cell expansion and ectopic follicle formation, 507–508
 - study conclusions, 510
 - in tumors, 509–510
 - Wnt pathway and, 504–505
- B cells. *See* Lymphocytes and the stem cell niche
- BCL-2* in leukemia, 445
- BCL-2* in Myc-induced lymphoma, 455–457
- BCR-ABL-induced leukemias and *INK4-ARF* locus
- background to CML therapies, 461–462
 - cellular self-renewal and, 462
 - cellular senescence and, 516, 519, 520
 - lineage specificity and self-renewal in CML, 462–463
 - modeling of Ph⁺ ALL in the mouse, 463–464
 - resistance to targeted therapy in Ph⁺ ALL, 464–466
 - study conclusions, 466
- β -cell biology
- adult progenitor cells study, 178
 - β -cell lineage, 175–176
 - cell reprogramming studies, 178–179
 - dedifferentiation from adult islet cells, 178
 - directed differentiation of cells, 176–177
 - genes associated with pancreatic development, 176
 - goal of deriving fully developed cells in culture, 177
 - injury model used to study, 178
 - pancreatic morphogenesis, 175
 - patient-specific iPS cell generation, 177
 - risks associated with growth-stimulating factors use, 178
 - signals influencing replication, 177–178
 - study conclusions, 179
- bHLH. *See* Myogenic bHLH regulatory factors
- Biomarker discovery
- imaging of neural progenitor cells and, 396–398
 - using metabolomics of neural progenitor cells, 393–396
- Bivalent domains, 259–260
- Blastema in salamander. *See also* Limb regeneration
- cell respect for developmental origin, 585
 - formation of, 584–585
- Blimp1/Prdm1, 9–10
- Blimp1-Prmt5, 13, 14
- Bmi1*
- adult stem cell self-renewal and, 544
 - deficiency within the lung, 486–487
 - and *Hoxb4* in HSCs (*see* *Hoxb4* and *Bmi1* in STR-HSCs and LTR-HSCs)
 - mammalian stem cell systems described, 237
- Bone morphogenetic protein (BMP), 39, 203, 338, 342. *See also* Transcriptional regulatory networks in embryonic stem (ES) cells
- Brain cancer and Notch pathway
- astrocytomas, 371–372
 - choroid plexus papilloma, 372
 - ependymomas, 372
 - medulloblastomas, 372
 - meningioma, 372
 - role in, 371
 - tumor stem cells, 372–373
- Brain disease and Notch signaling
- background to research, 403–404
 - insulin and DLL4 and downstream signaling, 404–405
 - insulin and DLL4 and stem cell survival, 405–406
 - insulin protection of dopamine neurons, 406
 - study conclusions, 406–408

- Brain Tumour (Brat), 524
 Brain tumor biology
 background to research, 411–413
 brain tumor stem cells in angiogenesis, 416
 cancer stem cell hypothesis, 412–413
 definition of brain tumor stem cells, 413–414
 derivation of brain tumor stem cells, 414–415
 gliomas in mouse models (*see* Astrocytomas)
 significance of stem cells in neuro-oncology, 415
 study conclusions and perspectives, 417
 targeting of brain tumor stem cells, 416–417
 therapeutic resistance and stem cells, 415–416
BRCA1 mutation, 475
 Breast cancer
 human breast stem and progenitor cells, 472–473
 mouse mammary gland
 background, 469
 cancer stem cell hypothesis and, 475–476
 cell of origin of breast cancer, 475
 hormonal regulation of MaSCs, 473
 identification of a luminal epithelial progenitor cell, 470–472
 lineage differentiation regulators, 474
 potential hierarchical models for MaSCs, 471–472
 prospective isolation of MaSC, 469–470
 regulatory pathways, 474–475
 study conclusions, 476
 Bronchioalveolar stem cells (BASCs), 479
 Bucket brigade relay mechanism, 62
- C**
- Caenorhabditis elegans*
 embryogenesis, 33–34
 tumor suppression in, 566, 566–567
 Cancer
 brain (*see* Astrocytomas; Brain cancer and Notch pathway; Brain tumor biology)
 breast (*see* Mammary gland, mouse)
 lung (*see* Lung stem cell biology)
 prostate (*see* Prostate, cancer stem cells)
 somatic cell reprogramming and dedifferentiation of cells in cancer, 171–172
 insights from myeloid leukemia, 171
 insights from plant studies, 269–270
 lin-28 studies, 172–173
 major goal of cancer research, 171
 pluripotent stem cells vs. tumorigenic cells, 173
 somatic cell reprogramming described, 172
 Cancer stem cell hypothesis
 brain tumors and, 412–413
 breast cancer and, 475–476
 CML and (*see* *INK4-ARF* locus)
- endogenous BCL-2 in Myc-induced lymphoma, 455–457
 evidence of transplantable cells in mouse hematopoietic tumors, 452–454
 implications for tumor propagation, 455
 lung stem cell biology and, 484–485
 nature of tumor maintaining cells, 454–455
 relevance to therapy, 455
 state of research, 598–599
 stem cells in the brain and, 422
 study conclusions, 457–458
 tumor propagation models, 451–452
 xenotransplantation concerns, 452
 Cap cells, 42–43
 Cardiac mesoderm development, 106–107
 Cardiomyocytes from human embryonic stem (hES) cells
 background to hES derivation, 127–128
 characterization of new cell lines, 129, 130, 131
 derivation of new cell lines, 128–129
 embryoid body-based cardiac differentiation of cells, 130–131
 establishment of enzymatically dispersable lines, 131–132
 methods, 132–133
 study conclusions, 133
 Caspases. *See* Ronin and caspases in embryonic stem (ES) cells
 Castration-resistant Nkx3.1-expressing cells (CARNs), 533–534
 CBC (Crypt Base Columnar), 351. *See also* *Lgr5* gene
 CD133 (Prominin-1), 414. *See also* Brain tumor biology
 Cellular senescence
 background, 513–514
 effects of during tumorigenesis and wound healing, 517–519
 endogenous triggers of, 519
 hyperproliferative signals in stellate cells, 517
 immortalization and self-renewal and, 520
 impact of immune response on activated stellate cells, 517
 p53 reactivation and PI3K signaling, 515
 p53 reactivation in mouse model, 514
 protection against liver fibrosis and, 515–516
 study conclusions, 520
 therapeutic strategies using, 519–520
 Choroid plexus papilloma (CPP), 372
 Chromatin in plant stem cell systems. *See* Repressor element 1-silencing transcription factor (REST)
 Chromatin regulators, 187
 Chronic myelogenous leukemia (CML), 443, 461. *See also* Leukemia stem cells
 Clara cell marker, 292, 481
 Clonal evolution model, 451
 c-Myc regulation of pathways
 epidermal stem cells and, 508
 Pten and p53 in glioblastoma, 433–434
 Wnt signaling and, 198
 Colon and *Lgr5* gene, 352–353
 Core promoter complexes. *See* TAFs and TRFs in skeletal muscle differentiation
- CPP (choroid plexus papilloma), 372
 Crypt Base Columnar (CBC), 351. *See also* *Lgr5* gene
 CySCs (somatic cyst stem cells), 138. *See also* *Drosophila*, male GSC lineages
 Cytoplasmic polyadenylation element (CPE), 34, 35
- D**
- Dam (DNA adenine methyltransferase), 525
Danio rerio. *See* Zebra fish
 Dasatinib therapy, 464–465
 Deltalike-4 (DLL4), 404–406. *See also* Brain disease and Notch signaling
 Determinate specification, 573–574, 598
 Diabetes. *See* β -cell biology
Dicer, 284
 Dimethylbenz[a]anthracene (DMBA), 510
 Direct reprogramming. *See* Reprogramming somatic cell identity
DLG, 567–568
 DLL4 (Deltalike-4), 404–406. *See also* Brain disease and Notch signaling
 DNA adenine methyltransferase (Dam), 525
Drosophila
 embryogenesis, 33–34
 epigenetic regulation by noncoding RNAs (*see* Piwi-interacting RNAs)
 female GSC lineages, 138
 function of Piwi proteins in germ cells, 285
 gene expression regulation (*see* Gene expression regulation)
 male GSC lineages
 hub cells in the stem cell niche, 138–140
 multiple cell types and niche function, 140
 regulation of self-renewal and differentiation, 141
 spermatogenesis as a model system, 138
 stem cell orientation and asymmetric division, 140–141
 switch to terminal differentiation, 142–143
 transit-amplifying cells and stem cell identity, 142
 mechanism of PcG transcriptional regulation, 257–258
 nervous system
 GMCs transformation in Prospero mutants, 526
 self-renewal vs. differentiation, 524–526
 symmetric vs. asymmetric division in, 523–524
 Piwi proteins in (*see* Piwi-interacting RNAs)
 stem cell niche (*see* Stem cell niche)
 tumor suppression in, 566–568
- E**
- E-cadherin-mediated cell adhesion, 41
 EGFR (epidermal growth factor receptor), 141

SUBJECT INDEX

605

Embryonic genome activation (EGA), 34
 Embryonic germ (EG) cells, 12–13
 Embryonic reprogramming. *See* Reprogramming and differentiation in mammals
 Embryonic stage stem cell self-renewal, 540–541
 Ependymomas, 372
 Epiblast stem cells (EpiSCs), 9
 Epidermal growth factor receptor (EGFR), 141
 Epidermal stem cells
 Notch pathway and signaling and, 508
 regulation by β -catenin (*see also* Skin stem cells)
 approaches to identifying and manipulating, 504
 background, 503–504
 β -catenin in cultured keratinocytes, 505–506
 β -catenin in mouse epidermis, 506–507
 β -catenin in tumors, 509–510
 β -catenin/Tcf/Lef complex, 508–509
 pathways that induce stem cell expansion and ectopic follicle formation, 507–508
 study conclusions, 510
 Wnt pathway and, 504–505
 Epigenetic reprogramming
 background, 9
 in early germ cells, 10–11
 EG vs. ES cells, 12
 genome resetting for totipotency, 11–12
 induced pluripotency of somatic cells (*see* Induced pluripotent stem cells)
 link between pluripotent stem and germ cells, 13–14
 PGCs dedifferentiation into EG cells, 12–13
 in plants and yeast
 epigenetic reprogramming and plant germ cells, 267–269
 heterochromatin and the cell cycle in yeast, 266
 heterochromatin regulation in plants, 266–267
 reprogramming and cancer, 269–270
 RNAi mechanism in fission yeast, 265–266
 small RNA-mediated transposon control, 269
 study conclusions, 270
 stem cell model for PGC specification, 9–10
 study conclusions and perspectives, 14
 EpiSCs (epiblast stem cells), 9
 Epithelial stem/progenitor cells function in the lung
 cell lineage analysis in the mouse, 293
 models of the mouse lung, 291–292
 study conclusions, 293–294
 Escort stem cells (ESCs), 39

F

Fetal and neonatal stage stem cell self-renewal
 acquiring of tissue-specific components, 541
 fetal germ-line, 541

fetal neural, 543
 hematopoietic, 542
 Fibroblast growth factors (FGFs), 67, 71, 338
 Fission yeast. *See* Yeast
 Flatworms (Platyhelminthes). *See* Planarian
 germ cell specification and regeneration
 Flk-1, 104, 105, 106
 Follicle bulge, 340–341
 Follicular stem cells (FSCs), 39
 Forse1 cells and rosette-stage NSCs, 380–382
 Fox pioneer factors, 121–124
 Full-grown oocyte (FGO), 33
 Fusome, 51

G

Ganglion mother cell (GMC), 524. *See also* *Drosophila*, nervous system
 Gata-3 and the mammary gland, 474
 GBM (glioblastoma multiforme), 427. *See also* Pten and p53 in glioblastoma
 GDNF (glial-cell-line-derived neurotrophic factor), 18, 28, 543
 Gene expression regulation
 germ-line RNA identification, 2
 germ plasm RNAs regulation, 2–5
 main modes of specifying germ cells, 1
 materials and methods, 6
 RNA regulators role in germ cell biology, 1
 study conclusions, 6–7
 study overview, 2
 transcriptional regulation of *nanos*, 6
 transcriptional repression in germ cells, 1
 Genetic competence. *See* Pioneer factors and genetic competence
 Germ cells, primordial. *See* Epigenetic reprogramming
 Germ granules, 1
 Germ-line stem (GS) cells, 18. *See also* Gene expression regulation
 in female *Drosophila*, 138
 germ cell colony definition, 19–20
 germ cell transplantation technique development, 17–18
 in male *Drosophila* (*see Drosophila*, male GSC lineages)
 niche described, 50–51
 Glial-cell-line-derived neurotrophic factor (GDNF), 18, 28, 543
 Glioblastoma multiforme (GBM). *See also* Brain cancer and Notch pathway
 Pten and p53 in
 acquired molecular profile of high-grade mouse gliomas, 429–430
 background to GBM research, 427–428
 c-Myc regulation of pathways, 433–434
 mutations in human primary GBM, 430
 results of combined loss in the mouse brain, 428–429
 results of inactivation of, 432–433
 stem/progenitor cell features, 430–431

study conclusions, 434–435
 research on mice
 acquired molecular profile of high-grade mouse gliomas, 429–430
 background to GBM research, 427–428
 c-Myc regulation of pathways, 433–434
 mutations in human primary GBM, 430
 results of combined loss in the mouse brain, 428–429
 results of inactivation of, 432–433
 stem/progenitor cell features, 430–431
 study conclusions, 434–435
 Gliomas, 411. *See also* Astrocytomas; Brain tumor biology
 GMC (ganglion mother cell), 524. *See also Drosophila*, nervous system
 GSCs. *See* Germ-line stem (GS) cells

H

Hair follicles
 adult stem cells vs. epidermal cells, 341–343
 embryonic roots of adult stem cells, 343–345
 follicle bulge and multipotency, 340–341
 Lgr5 gene in, 353–354
 melanocyte stem cells in (*see* Quiescent stem cells and MSCs)
 morphogenesis, 338–340
 HD (Huntington's disease), 404
 Heart, mammalian, 297–298. *See also* Islet-1 cardiovascular progenitors
 Hedgehog (Hh)
 epidermal stem cells and, 507–508
 induction of HSCs and, 114
 and the mammary gland, 474–475
 signaling role, 60
 Hematopoietic stem cells (HSCs)
 adult stage self-renewal, 543–544
 aging stage self-renewal, 545
 fetal and neonatal stage self-renewal, 542
 hierarchical structure of the human system, 439–441
 hierarchical structure of the mouse system, 439
 INK4-ARF locus (*see INK4-ARF* [*CDKN2A/B*] locus)
 leukemia stem cells
 immune surveillance, 445
 multistep model of disease progression, 445
 origin of, 442–444
 programmed cell death, 444–445
 self-renewal property, 444
 migration to bone marrow niches, 441–442
 renewal of short- and long-term (*see Hoxb4* and *Bmi1* in STR-HSCs and LTR-HSCs)
 stem cell-fate signaling property, 441
 stem cell research and, 17
 stem cell self-renewal at different ages
 adult stage, 543–545
 aging stage, 545–548

- Hematopoietic stem cells (HSCs)
(*continued*)
embryonic stage, 540–541
fetal and neonatal stage, 541–543
study conclusions, 445–446
zebra fish regulation model (*see* Zebra fish)
- Hes*, 405–406
- Heterochromatic silencing in plants and yeast
epigenetic reprogramming and plant germ cells, 267–269
heterochromatin and the cell cycle in yeast, 266
heterochromatin regulation in plants, 266–267
reprogramming and cancer, 269–270
RNAi mechanism in fission yeast, 265–266
small RNA-mediated transposon control, 269
study conclusions, 270
- Heterochromatin protein 1a (HP1a)
functional significance of PIWI-HP1a interaction, 278–279
HP1 binding and H3K9 methylation, 279
piRNAs and, 276–278
- Hex*, 120
- HGFAP-Cre* transgenic line, 428–431
- Histone methylation and demethylation, 258–259
- H-MRS (magnetic resonance spectroscopy), 390
- H-NMR. *See also* Metabolomics of neural progenitor cells
- Hoxb4* and *Bmi1* in STR-HSCs and LTR-HSCs
background to research, 555–556
Bmi1 HSCs expansion triggered by *HoxB4*, 559, 561–562
Bmi1 impairment of *HoxB4*-induced HSC expansion, 559
Bmi1 overexpression and HSC expansion, 556, 558, 559, 560–561
integration of multiple pathways by *Bmi1*, 562
lack of requirement for *Bmi1* in embryonic HSC expansion, 556
pathways regulated by *Bmi1* and *HoxB4*, 562
requirement for *Bmi1* in adult HSC activity, 556
rescue of *Bmi1* function by *HoxB4*, 559, 560
study conclusions, 562–563
- HOX* genes and Polycomb group proteins, 256
- HSCs. *See* Hematopoietic stem cells
- HTA1* segregation, 82
- Huntington's disease (HD), 404
- I**
- Imatinib therapy, 461, 464–465
- Immortal strand hypothesis
lack of evidence of in yeast, 86–87
segregating immortal DNA strands, 84–85
testing, 85–86
- Induced pluripotent stem (iPS) cells, 33, 149
- elements of a high efficiency system, 160
- factors influencing reprogramming efficiency, 159–160
- partially reprogrammed cells study, 158–159
- reprogramming and insertional mutagenesis, 160
- research background, 157–158
study conclusions, 161
transcription-factor-induced reprogramming, 158
- Inductive specification, 573–574, 598
- INK4-ARF (CDKN2A/B)* locus
background to CML therapies, 461–462
cellular self-renewal and, 462
cellular senescence and, 516, 519, 520
lineage specificity and self-renewal in CML, 462–463
modeling of Ph⁺ ALL in the mouse, 463–464
resistance to targeted therapy in Ph⁺ ALL, 464–466
study conclusions, 466
suppression by PcG proteins, 256–257
- Insulin and DLL4, 404–406
- Intercalary regeneration, 588
- Intermediate progenitor cells (IPCs), 367.
See also Notch pathway and signaling
- IPS. *See* Induced pluripotent stem cells
- Islet-1 cardiovascular progenitors
anchoring of atrial chambers and great veins, 302
cardiac outflow tract, 300, 302
cell-fate map, 298–300
congenital heart disease and, 300, 301, 302–303
embryonic development of mammalian heart, 297–298
proepicardium as a source of cardiomyocytes, 300
retrodifferentiation, 303
Wnt/ β -catenin signaling, 300, 302
- J**
- Jagged (Jag), 404
- K**
- K14 promoter/ β -catenin model, 506, 507, 508, 510
- Kinetochore asymmetry in yeast. *See* Stem cell asymmetry in yeast
- KNOX* proteins, 245–246, 247. *See also* Stem cell homeostasis regulation in plants
- K-ras*, 486
- L**
- L1 cell adhesion molecule (L1CAM), 416
- Leukemia inhibitory factor (LIF), 203
- Leukemia stem cells
immune surveillance, 445
INK4-ARF locus and therapy research (*see* *INK4-ARF [CDKN2A/B]* locus)
multistep model of disease progression, 445
origin of, 442–444
programmed cell death, 444–445
self-renewal property, 444
- LGL*, 567–568
- Lgr5* gene
in the colon, 352–353
in hair follicles, 353–354
in small intestine, 351–352
study conclusions, 354–355
study methods, 354
- Limb regeneration
ALM and ectopic limb formation, 587
blastema cell respect for developmental origin, 584–585
blastema formation, 584–585
epithelial wound healing, 583–584
PD and intercalary regeneration, 588
PD and positional memory, 588
PD identity and tissue heterogeneity, 589–590
retinoic-acid-induced proximalization, 588–589
role of nerves during regeneration, 585–587
study conclusions and perspectives, 590
- Lin-28* studies in cancer research, 172–173
- Lipocalins, 63
- Liver
embryonic origins of, 119
fibrosis and cell senescence, 515–519
- Long-term repopulating hematopoietic stem cells (LTR-HSCs), 555.
See also *Hoxb4* and *Bmi1* in STR-HSCs and LTR-HSCs
- Lung stem cell biology
background, 479–480
cancer stem cell hypothesis and, 484–485
epithelial repair, 291–293
epithelial stem/progenitor cells function
cell lineage analysis in the mouse, 293
models of the mouse lung, 291–292
study conclusions, 293–294
genetic approaches for cancer stem cells, 485
identification of BASCs, 480
injury models used to identify putative stem cells
cell ablation strategies, 481
Clara cell resistance to naphthalene, 481
partial pneumonectomy and, 481
reaction to bleomycin treatment, 481
stem cell model for distal lung homeostasis, 482
label retention as a lineage tracer, 482–483
lineage tracing in the lung, 482
pathways involved in BASC function, 485–487
search for additional markers, 485
study conclusions, 487
transplantation of lung stem cells, 483–484
- Lymphocytes and the stem cell niche
asymmetric cell division and immunity, 75
asymmetric cell division of clonally selected T cells, 76–77
cell-fate diversity model, 77–78
direct reprogramming of mature lymphocytes, 150–152

SUBJECT INDEX

607

- facultative polarity establishment, 75, 76f
 generation of cell-fate diversity, 73–74
 nuclear transfer of mature lymphocytes, 150
 possibility of asymmetric cell division in other blood lineages, 77
 regeneration of lymphocytes for immunity, 74–75
 of terminally differentiated lymphocytes, 149–150
 Lymphoma, 455–457
 Lysine demethylases (KDM), 258
- M**
- Magnetic resonance spectroscopy (H-MRS), 390
 Mammalian spermatogenesis. *See* Spermatogonial stem cells (SSCs)
 Mammary gland, mouse
 background, 469
 cancer stem cell hypothesis and, 475–476
 cell of origin of breast cancer, 475
 hormonal regulation of MaSCs, 473
 human breast stem and progenitor cells, 472–473
 identification of a luminal epithelial progenitor cell, 470–472
 lineage differentiation regulators, 474
 potential hierarchical models for MaSCs, 471–472
 prospective isolation of MaSCs, 469–470
 regulatory pathways, 474–475
 study conclusions, 476
 Mammary stem cell (MaSC). *See* Mammary gland, mouse
 MAPK14 and lung cancer stem cells, 486
 MaSC (mammary stem cell). *See* Mammary gland, mouse
 Maternal to zygotic transition (MTZ) in animals and plants
 biological significance, 97
 degradation of maternal factors during, 96–97
 early embryogenesis, 89–90
 MTZ defined, 90–91
 timing of, 91–93
 ZGA mechanism, 95–96
 ZGA timing, 93–95
 Matisse, 211
 MBT (midblastula transition), 34, 90
 Medulloblastomas, 372
 Melanocyte stem cells (MSCs), 67. *See also* Quiescent stem cells and MSCs
 Meningioma, 372
 Metabolomics of neural progenitor cells
 background to metabolomic fingerprinting, 389–390
 biomarker discovery using, 393–396
 data acquisition, 390–391
 imaging of neural progenitor cells and, 396–398
 signal processing, 392–393
 study conclusions, 399
 microRNAs, 42, 227
 Midblastula transition (MBT), 34, 90
 Miranda, 524–526
Monosiga, 568, 569, 570
 Morphogens, 62–63
- Mouse embryonic stem (ES) cells
 β -catenin in mouse epidermis, 506–507
 cellular senescence and p53 reactivation, 514
 epidermal stem cells, 506–507
 epithelial stem/progenitor cells
 function in the lung, 291–293
 evidence of transplantable cells in hematopoietic tumors, 452–454
 evolution of TSGs in vertebrates and, 568–569
 gastrulation and the primitive streak, 102–103
 glioblastoma multiforme research
 acquired molecular profile of high-grade mouse gliomas, 429–430
 background to GBM research, 427–428
 c-Myc regulation of pathways, 433–434
 mutations in human primary GBM, 430
 results of combined loss in the mouse brain, 428–429
 results of inactivation of, 432–433
 stem/progenitor cell features, 430–431
 study conclusions, 434–435
 hierarchical structure of hematopoietic system, 439
 malignant astrocytoma model (*see* Astrocytomas)
 mammary gland
 background, 469
 cancer stem cell hypothesis and, 475–476
 cell of origin of breast cancer, 475
 hormonal regulation of MaSCs, 473
 human breast stem and progenitor cells, 472–473
 identification of a luminal epithelial progenitor cell, 470–472
 lineage differentiation regulators, 474
 potential hierarchical models for MaSCs, 471–472
 prospective isolation of MaSCs, 469–470
 regulatory pathways, 474–475
 study conclusions, 476
 model for PGC specification, 9–10
 modeling of Ph^+ ALL, 463–464
 Pten and p53 in glioblastoma
 acquired molecular profile of high-grade mouse gliomas, 429–430
 background to GBM research, 427–428
 c-Myc regulation of pathways, 433–434
 results of combined loss in the mouse brain, 428–429
 results of inactivation of, 432–433
 stem/progenitor cell features, 430–431
 study conclusions, 434–435
 reactivation and PI3K signaling, 515
 reactivation in mouse model, 514
 testis system
 anatomical overview, 25–26
 functional hierarchy in, 28–29
 genetic labeling of A_{undiff} , 28
 microenvironmental niche in, 29–30
- A_s model, 26–27, 28
 posttransplantation spermatogenic colony formation, 27–28
 seminiferous epithelial cycle, 27
 transcriptional regulatory networks in background, 203
 core network, 204–205
 expanding, 205–207
 Nanog/Sall4 transcription circuit, 204
 Oct4/Sox2 transcription circuit, 203–204
 study conclusions, 207
 MSCs (melanocyte stem cells), 67. *See also* Quiescent stem cells and MSCs
 MTZ. *See* Maternal to zygotic transition in animals and plants
 Myc-induced lymphoma, 455–457
 Myeloid leukemia, 171
 Myogenic bHLH regulatory factors
 molecular regulation of myogenic factor function, 326–327
 Myf5 and MyoD regulation of myogenic lineages
 development, 326
 MyoD family of transcription factors, 325–326
- N**
- NAG, 586–587
 Nanog/Sall4 transcription circuit, 204
 Nanog transcription factor
 control of pluripotency
 dual role of pluripotency factors, 198
 identification of Nanog-associated proteins, 195–196
 identification of target genes, 197–198
 Nanog protein function, 199
 Oct4 dependence of chromatin structure, 199–200
 protein interaction network surrounding Nanog, 196–197
 study conclusions, 200
 embryonic stem cell self-renewal and, 540–541
 mammalian stem cell systems described, 236–238
 reprogramming and differentiation role, 35–36, 172
Nanos, 6, 576–577
 Natural killer (NK) cell, 517
 NEPs (neuroepithelial progenitors), 367. *See also* Notch pathway and signaling
 Nestin, 373, 403
 Neural stem/progenitor cells (NSCs), 227
 adult germinal layer, 358
 adult stage self-renewal, 544–545
 aging stage self-renewal, 546
 astroglial cell origination from radial glia, 358
 background to research on the adult brain, 357–358
 differentiation through REST expression (*see* Repressor element 1-silencing transcription factor)
 in *Drosophila* nervous system
 GMCs transformation in Prospero mutants, 526

- Neural stem/progenitor cells (NSCs),
(*continued*)
self-renewal vs. differentiation,
524–526
symmetric vs. asymmetric division
in, 523–524
fetal stage self-renewal, 543
metabolomics of
background to metabolomic
fingerprinting, 389–390
biomarker discovery using, 393–396
data acquisition, 390–391
imaging of neural progenitor cells
and, 396–398
signal processing, 392–393
study conclusions, 399
migrating neuroblasts and
heterogeneity, 360
Notch pathway role in neurogenesis
(*see* Notch pathway and
signaling)
role in tumor initiation and program-
ming (*see* Astrocytomas)
rosette stage (*see* Rosette-stage NSCs)
spatial specification of SVZ
progenitors, 361–363
study conclusions, 363
temporal specification of SVZ
progenitors, 360–361
Type B cell generation of interneurons
in the OB, 358–360
Neuroepithelial progenitors (NEPs), 367.
See also Notch pathway and
signaling
Neurogenin3 (Ngn3), 28
Nf1, 422. *See also* Astrocytomas
Niche. *See* Stem cell niche; Stem cell/
niche interactions
NK (natural killer) cell, 517
Nkx3.1, 530, 533–534
Notch pathway and signaling
aging stem cell self-renewal and,
546–548
background, 367
brain cancer and, 371–373
brain disease and
background to research, 403–404
insulin and DLL4 and downstream
signaling, 404–405
insulin and DLL4 and stem cell
survival, 405–406
insulin protection of dopamine
neurons, 406
study conclusions, 406–408
current research focus, 369
differential signaling in neural
progenitors, 369–371
epidermal stem cells and, 508
neocortical development and neural
progenitors, 367–368
receptor signaling and progressive
brain disease (*see* Brain
disease and Notch signaling)
signaling in neural progenitors, 368
study conclusions, 373
Numb, 524
- O**
- Oct4
dependence of chromatin structure on,
199–200
reprogramming and differentiation
role, 35–36, 172
- Oct4/Sox2 transcription circuit
embryonic stem cell self-renewal and,
540–541
mammalian stem cell systems, 236–238
in regulatory networks, 203–204
Olfactory bulb (OB), 357, 421. *See also*
Astrocytomas; Neural
stem/progenitor cells (NSCs)
Optic lobe in *Drosophila*, 523–524
- P**
- P16^{Ink4a}, 237, 545, 546
P18^{Ink4c}, 485
P19^{Arf}, 545, 546
P27, 485
p53, 422. *See also* Astrocytomas
P53 in glioblastoma. *See* Pten and p53 in
glioblastoma
P63-expressing progenitors, 532
P63 transcription factor, 335
Pachytene piRNAs, 286
Pancreas. *See* β -cell biology; Pioneer
factors and genetic competence
Parkinson's disease (PD), 403, 407–408
Partner of Numb (Pon), 524
Pax3/7 and skeletal muscle stem cells
background to research, 307
differentiation into skeletal muscle,
311–312
function of Pax3/7 in stem cells, 310
implications of two waves of
myogenesis, 310
migration of satellite cells, 311
multipotency of Pax-positive cells,
310–311
muscle satellite cell, 308–310
myogenesis in the embryo, 307–308
proliferation promotion, 311
self-renewal vs. differentiation,
312–313
stem cell survival and, 311
study conclusions, 313–314
PCG specification in vivo, 9–10
PD (Parkinson's disease), 403, 407–408
PD (proximodistal) axis, 588, 589–590
Pelo, 41–42
Peritubular myoid cells, 26
PGCs (primordial germ cells), 9, 18
P granules, 1
Phosphoinositol-3 kinase (PI3K), 416,
486, 515
Pioneer factors and genetic competence
developmental competence of the
endoderm, 120–121
FoxD3 and demethylation mark,
122–124
Fox factors and chromatin opening,
121–122
future directions, 124
inductive mesodermal signaling,
119–120
multipotency of foregut endoderm,
120
transcription factor binding in mitotic
chromatin, 122
Piwi-interacting RNAs (piRNAs)
Argonaute/Piwi proteins and, 273–274
background, 273
epigenetic function in the soma, 275
functional significance of PIWI-HP1a
interaction, 278–279
function of Piwi proteins in germ
cells, 285
guidance hypothesis, 279–280
HP1a binding and H3K9 methylation
and, 279
interaction with HP1A, 276–278
regulation of the epigenetic state in
somatic cells, 276, 277
role in epigenetic regulation in
somatic cells, 274–275
small RNA silencing pathways in
animals
function of Piwi proteins in germ
cells, 284–285
general mechanisms of RNA
silencing, 283–284
miRNA and siRNA pathways in
mammalian stem and germ
cells, 284
piRNA populations in germ cells,
285–286
Piwi/piRNA pathway as a mediator
of epigenetic memory, 286–287
study conclusions, 287–288
study conclusions, 280
Planarian germ cell specification and
regeneration
choanoflagellates and tumor
suppression, 567
determinate and inductive
specification, 573–574
nanos function in germ cells, 576
nanos-positive presumptive germ
cells, 576–577
neoblasts and, 577
planarian biology, 574–575
plasticity of germ cells and committed
neoblasts, 578
S. mediterranea as a model organism,
575–576
study conclusions, 578–579
Plants
epigenetic reprogramming and plant
germ cells, 267–269
heterochromatin and the cell cycle in
yeast, 266
heterochromatin regulation in plants,
266–267
MTZ in (*see* Maternal to zygotic
transition in animals and
plants)
regulation of homeostasis
epigenetic regulation of stem cell
fate, 247
by *KNOX* homeodomain proteins,
245, 247
negative regulators of *KNOX* gene
expression, 245–246
root and shoot meristems function
and organization, 243–244
study conclusions, 248–249
WUS-CLV feedback loop,
244–245
reprogramming and cancer, 269–270
RNAi mechanism in fission yeast,
265–266
small RNA-mediated transposon
control, 269
stem cell factors in
analysis of state transitions in,
239–240
chromatin state modification,
235–236
histone code hypothesis, 235–236
mammalian stem cell systems
described, 236–238

SUBJECT INDEX

609

- stem cell systems described, 238–239
- study conclusions, 270
- Platyhelminthes (flatworms). *See* Planarian
- germ cell specification and regeneration
- PluriNet, 211
- Pluripotent stem cells (PSCs)
 - cardiac mesoderm development, 106–107
 - endoderm formation from, 104–105
 - genetic modification of, 107–108
 - induced (*see* Induced pluripotent stem cells)
 - mesoderm development, 105–106
 - mouse gastrulation and the primitive streak, 102–103
 - primitive streak formation from, 104
 - regulation involving enzymes (*see* Ronin and caspases in embryonic stem [ES] cells)
 - research background, 101–102
 - signaling pathways as key regulators, 103
 - strategies for differentiation, 103–104
 - transcriptional network controlling dual role of pluripotency factors, 198
 - identification of Nanog-associated proteins, 195–196
 - identification of target genes, 197–198
 - Nanog protein function, 199
 - Oct4 dependence of chromatin structure, 199–200
 - protein interaction network surrounding Nanog, 196–197
 - study conclusions, 200
- Polar granules, 1
- Polycomb group proteins (PcGs), 187
 - bivalent domains, 259–260
 - DNA methylation and, 260–261
 - factors downstream from PcG proteins, 255–257
 - histone methylation and demethylation and, 258–259
 - mechanism of, 257–258
 - PcG proteins function and interactions, 253–255
 - PcG target genes, 255
- Polycomb repressive complexes (PRCs), 253. *See also* Polycomb group proteins
- Pon (Partner of Numb), 524
- Porcupine (Porc), 61
- POU family transcription factor. *See* Oct4
- Primitive streak (PS), 102–103, 104. *See also* Pluripotent stem cells (PSCs)
- Primordial germ cells (PGCs), 9, 18
- Prmt5, 13–14
- Prominin-1 (CD133), 414. *See also* Brain tumor biology
- Prospero, 524–526
- Prostate
 - cancer stem cells
 - background to research, 491–492
 - cancer models, 497
 - cell of origin studies, 497–498
 - identification and isolation of prostate stem cells, 495–497
 - in prostate cancer, 498–499
 - prostate gland and adult prostate stem cells, 492–493
 - study approaches, 493–495
 - study conclusions, 499
- epithelium
 - cell of origin for prostate cancer, 535–536
 - development and regeneration of the prostate gland, 530
 - evidence of stem cells in, 530–531
 - features of, 529–530
 - localization of stem cells in, 531–532
 - progenitor population
 - identification, 533–534
 - stem cell localization and lineages models, 534–535
- Proximodistal (PD) axis, 588, 589–590
- PSCs. *See* Pluripotent stem cells
- Pten*
 - astrocytomas and, 422
 - evolution of TSGs in vertebrates and, 568–569
 - in lung tumorigenesis, 486
- Pten and p53 in glioblastoma
 - acquired molecular profile of high-grade mouse gliomas, 429–430
 - background to GBM research, 427–428
 - c-Myc regulation of pathways, 433–434
 - mutations in human primary GBM, 430
 - results of combined loss in the mouse brain, 428–429
 - results of inactivation of, 432–433
 - stem/progenitor cell features, 430–431
 - study conclusions, 434–435
- Q**
- Quiescent stem cells and MSCs
 - cellular compartments in MSC system, 68
 - FACs used to analyze MSC features, 69–70
 - induction of quiescent MSCs, 70–71
 - MSC signature, 68, 69f
 - MSCs value as a model, 67–68
 - Notch's role in MSC maintenance, 70
 - study conclusions, 71
- R**
- RA (retinoic-acid-induced proximalization), 588–589
- Radial glial cells (RGCs), 367. *See also* Notch pathway and signaling
- RB and evolution of TSGs in vertebrates, 568–569
- Reactive oxygen species (ROS), 43
- Repeat-associated small interfering RNAs (rasiRNAs), 285
- Repressor element 1-silencing transcription factor (REST)
 - defined, 227
 - function of, 228, 231
 - interaction with the RD1 domain, 227–228
 - in medulloblastoma, 229–230
 - neuronal differentiation through muscle progenitor cells, 229
 - neuronal differentiation through NSC, 228–229
 - role in the inner cell mass of blastocysts, 231
 - self-renewal and differentiation regulation, 230–231
- study conclusions, 231–232
- as a tool to understand cellular flexibility, 231
- Reprogramming, epigenetic
 - background, 9
 - in early germ cells, 10–11
 - EG vs. ES cells, 12
 - genome resetting for totipotency, 11–12
 - induced pluripotency of somatic cells (*see* Induced pluripotent stem cells)
 - link between pluripotent stem and germ cells, 13–14
 - PGCs dedifferentiation into EG cells, 12–13
 - stem cell model for PGC specification, 9–10
 - study conclusions and perspectives, 14
- Reprogramming and differentiation in mammals
 - CPE in maternal messages, 35
 - embryogenesis in metazoans, 33, 34f
 - embryonic expression of genes effecting reprogramming, 36
 - oocyte-to-embryo transition and stem cell genes, 36–37
 - pluripotency regulatory circuitry, 35–36
 - programmed degradation of maternal mRNAs, 34
 - stabilization of maternal mRNAs, 34–35
 - study conclusions, 37
- Reprogramming and epigenetic inheritance in plants and yeast
 - heterochromatin and the cell cycle in yeast, 266
 - heterochromatin regulation in plants, 266–267
 - plant germ cells and, 267–269
 - reprogramming and cancer, 269–270
 - RNAi mechanism in fission yeast, 265–266
 - small RNA-mediated transposon control, 269
 - study conclusions, 270
- Reprogramming somatic cell identity
 - cancer and (*see* Cancer, somatic cell reprogramming)
 - cellular reprogramming defined, 147–148
 - direct reprogramming mechanism, 152
 - direct reprogramming of mature lymphocytes, 150–152
 - into ES-like cells by defined factors, 149
 - by molecularly undefined mechanisms, 148–149
 - nuclear cloning vs. direct reprogramming, 153–154
 - nuclear transfer of mature lymphocytes, 150
 - research background, 147
 - stochastic events during direct reprogramming, 152
 - of terminally differentiated lymphocytes, 149–150
- REST. *See* Repressor element 1-silencing transcription factor
- Retinoic-acid (RA)-induced proximalization, 588–589
- RGCs (radial glial cells), 367. *See also* Notch pathway and signaling

- RM (root meristem), 238–239
 RMS (rostral migratory stream), 357, 421
 RNA-induced transcriptional silencing (RITS) complex, 266, 273
 RNA silencing pathways. *See* Small RNA silencing pathways
 R-NSCs. *See* Rosette-stage NSCs (R-NSCs)
 Ronin and caspases in embryonic stem (ES) cells
 caspases as mediators of ES cell differentiation, 163–164
 cellular identity research and, 167–168
 ectopic expression of *Ronin* in ES cells, 166
 pluripotency and, 166–167
 Ronin as a candidate pluripotency factor, 164–165
 Ronin expression pattern during development, 165
 Ronin knockout results, 165–166
 Ronin structural features, 165
 Root meristem (RM), 238–239
 ROS (reactive oxygen species), 43
ROSA26, 107–108
 Rosette-stage NSCs (R-NSCs)
 background to research, 377
 developmental potency and NSCs, 378–379
 difficulties of using NSCs to derive specialized neuron types, 379
 embryonic stem cells and, 379
 Forse1 cells and, 380–382
 growth requirements and potential, 382
 molecular-level development, 382–384
 neural rosettes described, 379–380
 neural stem cells studies, 377–378
 stem cell nature, cytoarchitecture, and progress in, 380
 study conclusions and perspectives, 384
 Rostral migratory stream (RMS), 357, 421
- S**
- SA- β -gal (senescence-associated β -galactosidase), 513
Saccharomyces cerevisiae. *See* Yeast
 Salamander limb regeneration. *See* Limb regeneration
 SAM (shoot apical meristem), 238–239
 Satellite cells in muscle. *See* Skeletal muscle, satellite cells
Schmidtea mediterranea, 575
 SCNT (somatic cell nuclear transfer), 147
Scrib, 567–568
 Sebaceous gland (SG), 343
 Second heart field (SHF), 297. *See also* Islet-1 cardiovascular progenitors
 Seminiferous tubules, mouse, 17, 25
 Senescence-associated β -galactosidase (SA- β -gal), 513
 Senescence. *See* Cellular senescence
 Sertoli cells, 26
 SG (sebaceous gland), 343
 SGZ (subgranular zone), 421
 SHF (second heart field), 297. *See also* Islet-1 cardiovascular progenitors
 Shoot apical meristem (SAM), 238–239
 Short-term repopulating hematopoietic stem cells (STR-HSCs), 555. *See also* *Hoxb4* and *Bmi1* in STR-HSCs and LTR-HSCs
 Skeletal muscle
 Pax3/7 and stem cells
 background to research, 307
 function of Pax3/7 in stem cells, 310
 implications of two waves of myogenesis, 310
 migration of satellite cells, 311
 multipotency of Pax-positive cells, 310–311
 muscle satellite cell, 308–310
 myogenesis in the embryo, 307–308
 Pax3/7 differentiation into skeletal muscle, 311–312
 Pax 7 role in myogenic specification of, 324–325
 promotion of proliferation, 311
 self-renewal vs. differentiation, 312–313
 stem cell survival and, 311
 study conclusions, 313–314
 satellite cells
 adult myogenesis and, 318
 aging of muscle stem cells and, 320–321
 background to research, 323
 developmental origins of, 317–318
 heterogeneity and, 318–319
 isolation of stem cells, 319–320
 maintenance of the satellite cell compartment, 327–328
 molecular regulation of myogenic factor function, 326–327
 molecular regulation of Pax7 function, 325
 muscle disease and, 320
 Myf5 and MyoD regulation of myogenic lineages development, 326
 MyoD family of transcription factors, 325–326
 Pax 7 role in myogenic specification of, 324–325
 Pax family of transcription factors, 323–324
 stem cell niche, 327
 study conclusions and perspectives, 321, 328–329
 TAFs and TRFs in skeletal muscle differentiation
 background, 217–218
 coordinated switching during skeletal muscle specialization, 223–224
 differential expression during myoblast differentiation, 218–219
 differential expression in skeletal muscle, 219–220
 expression of TBP-related factor, 221
 myogenic differentiation and, 221–223
 Skin stem cells. *See also* Epidermal stem cells
 adult follicle stem cells vs. epidermal cells, 341–343
 basal epidermal cells architecture and function, 333–334
 basal-to-spinous switch, 335–336
 embryonic roots of adult stem cells, 343–345
 epidermal homeostasis, 336–338
 hair follicle bulge and multipotency, 340–341
 hair follicle morphogenesis, 338–340
 homeostasis in the sebaceous gland, 343
 Lgr5 gene in hair follicles, 353–354
 p63 transcription factor, 335
 regulatory mechanisms, 334–335
 stem cell niches, 345–346
 study conclusions, 346
 terminal differentiation process, 336
 Small intestine and the *Lgr5* gene, 351–352
 Small RNA silencing pathways
 function of Piwi proteins in germ cells, 284–285
 general mechanisms of RNA silencing, 283–284
 miRNA and siRNA pathways in mammalian stem and germ cells, 284
 piRNA populations in germ cells, 285–286
 Piwi/piRNA pathway as a mediator of epigenetic memory, 286–287
 study conclusions, 287–288
 SOD (superoxide dismutase), 43
 Somatic cell identity reprogramming. *See* Reprogramming somatic cell identity
 Somatic cell nuclear transfer (SCNT), 147
 Somatic cyst stem cells (CySCs), 138
 Sox17 transcriptional regulator, 542
 Sox2 transcription factor, 545
 embryonic stem cell self-renewal and, 540–541
 in mammalian stem cell systems, 236–238
 reprogramming and differentiation role, 35–36, 172
 Spermatogonial stem cells (SSCs)
 functional analyses used to define, 19
 germ cell colony definition, 19–20
 germ cell transplantation technique development, 17–18
 long-term culture system development, 18–19
 mouse testis system
 anatomical overview, 25–26
 functional hierarchy in, 28–29
 genetic labeling of A_{undiff} , 28
 A_s model, 26–27, 28
 niche in, 29–30
 posttransplantation spermatogenic colony formation, 27–28
 seminiferous epithelial cycle, 27
 proliferation vs. self-renewal, 19
 study conclusions and perspectives, 20–21
 technical problems during research, 20
 Spitz, 60
 Stem cell asymmetry in yeast
 asymmetric segregation of kinetochore proteins, 82–84
 asymmetry of spindle pole body segregation, 84
 histone *HTAI* segregation, 82
 lack of evidence of immortal strands in yeast, 86–87
 segregating immortal DNA strands, 84–85
 selective centromere segregation, 87
 study conclusions and perspectives, 87
 study overview, 81

SUBJECT INDEX

611

- testing the immortal strand hypothesis, 85–86
- tracking nonencoded protein, 82
- Stem cell homeostasis regulation in plants
- epigenetic regulation of stem cell fate, 247
- by *KNOX* homeodomain proteins, 245, 247
- negative regulators of *KNOX* gene expression, 245–246
- root and shoot meristems function and organization, 243–244
- study conclusions, 248–249
- WUS-CLV feedback loop, 244–245
- Stem cell niche
- in the brain, 421–422
- description and function, 596
- follicle, 51–52, 53f
- fusome role, 51
- germ line, 50–51
- implications as dynamic entities, 55
- implications for stem cell therapy, 55–56
- importance of studying in vivo, 55
- intestinal, and daughter cell programming, 53–54
- lymphocytes and
- asymmetric cell division and immunity, 75
- asymmetric cell division of clonally selected T cells, 76–77
- cell-fate diversity model, 77–78
- direct reprogramming of mature lymphocytes, 150–152
- facultative polarity establishment, 75, 76f
- generation of cell-fate diversity, 73–74
- nuclear transfer of mature lymphocytes, 150
- possibility of asymmetric cell division in other blood lineages, 77
- regeneration of lymphocytes for immunity, 74–75
- of terminally differentiated lymphocytes, 149–150
- in mouse testis, 29–30
- in plants, 243
- quiescent stem cells (*see* Quiescent stem cells and MSCs)
- regulation of stem cells (*see* Repressor element 1-silencing transcription factor; Transcription regulation by Polycomb group proteins)
- self-correcting nature of, 53
- skeletal muscle satellite cells, 327
- stroma's role in cancer, 55
- study methods, 49–50
- study overview, 49
- work as dynamic integrated units, 54–55
- Stem cell/niche interactions
- BMP niche signal control of GSC self-renewal, 40–41
- competition in stem cell regulation, 43
- control of GSCs self-renewal, 41–42
- control of niche formation and maintenance, 42–43
- E-cadherin-mediated cell adhesion, 41
- FSCs control of their self-renewal, 44
- migration of HSCs to bone marrow niches, 441–442
- signal regulation and (*see* Wnt signaling/pathway)
- skin stem cells and, 345–346
- stem cell aging and, 43
- study conclusions and future directions, 44–46
- study overview, 39–40
- Stem cell research
- asymmetric cell division, 596–597
- cancer stem cell hypothesis, 598–599
- criteria for deriving models for stem cells, 594–595
- directed differentiation of pluripotent stem cells (*see* Pluripotent stem cells)
- functional assays for stem cells, 595–596
- identification of multiple stem cell types, 593–594
- identification of non-quiescent stem cells, 594
- mammalian stem cell systems
- described, 236–238
- niche description and function, 596
- Polycomb group proteins and (*see* Polycomb group proteins)
- positional identities of homogenous multipotent cells, 594
- properties of classical stem cells, 593
- regulation of embryonic and tissue stem cells, 597
- reprogramming of differentiated cells, 597–598
- therapeutic potential of transdifferentiation, 598
- Stem cell self-renewal at different ages
- adult stage
- differences relative to fetal stem cells, 543
- germ line, 543
- hematopoietic, 543–544
- neural, 544–545
- aging stage
- hematopoietic, 545
- insights from other systems, 546–548
- neural, 546
- background, 539–540
- embryonic stage, 540–541
- fetal and neonatal stage
- acquiring of tissue-specific components, 541
- germ line, 541
- hematopoietic, 542
- neural, 543
- study conclusions and perspectives, 548
- Stem cell systems biology
- from attractors to epigenetic landscapes, 213–214
- cellular senescence and (*see* Cellular senescence)
- long-term self-renewal of *Lgr5* stem cells
- in the colon, 352–353
- in hair follicles, 353–354
- in small intestine, 351–352
- study conclusions, 354–355
- study methods, 354
- mathematical networks applied to molecular-level systems, 211–212
- from networks to dynamic stem cell attractors, 212–213
- stem cell factors in plants
- analysis of state transitions in, 239–240
- chromatin state modification, 235–236
- histone code hypothesis, 235–236
- mammalian stem cell systems
- described, 236–238
- stem cell systems described, 238–239
- study conclusions, 214
- STR-HSCs. *See* Short-term repopulating hematopoietic stem cells
- Subgranular zone (SGZ), 421
- Subventricular zone (SVZ), 357, 421. *See also* Astrocytomas; Notch pathway and signaling
- Superoxide dismutase (SOD), 43
- Swim, 62–63
- T**
- T1x nuclear receptor, 545
- TAFs and TRFs in skeletal muscle differentiation
- background, 217–218
- coordinated switching during skeletal muscle specialization, 223–224
- differential expression during myoblast differentiation, 218–219
- differential expression in skeletal muscle, 219–220
- expression of TBP-related factor, 221
- myogenic differentiation and, 221–223
- T cells. *See* Lymphocytes and the stem cell niche
- T-EGFP, 104, 105, 106
- TFIID. *See* TAFs and TRFs in skeletal muscle differentiation
- TGF- β 1 (transforming growth factor- β 1), 475, 547–548
- Thanatos-associated protein (THAP), 164–165
- TIC (tumor-initiating cells), 427
- Transcriptional network controlling pluripotency
- dual role of pluripotency factors, 198
- identification of Nanog-associated proteins, 195–196
- identification of target genes, 197–198
- Nanog protein function, 199
- Oct4 dependence of chromatin structure, 199–200
- protein interaction network surrounding Nanog, 196–197
- study conclusions, 200
- Transcriptional regulatory circuitry in embryonic stem (ES) cells
- core circuitry model, 189
- mapping the core network, 184–185
- mechanisms controlling eukaryotic transcription, 183–184
- noncoding RNAs and, 188
- Polycomb and Trithorax group proteins and, 187
- reprogramming of, 189–190
- studies of key transcription factors, 185–187
- study conclusions, 190
- Wnt signaling pathway and, 187–188
- Transcriptional regulatory networks in embryonic stem (ES) cells
- background, 203
- core network, 204–205

Transcriptional regulatory networks in embryonic stem (ES) cells (*continued*)
 expanding, 205–207
 Nanog/Sall4 transcription circuit, 204
 Oct4/Sox2 transcription circuit, 203–204
 study conclusions, 207
 Transcription regulation by Polycomb group proteins
 bivalent domains, 259–260
 DNA methylation and, 260–261
 factors downstream from PcG proteins, 255–257
 histone methylation and demethylation and, 258–259
 mechanism of, 257–258
 PcG proteins function and interactions, 253–255
 PcG target genes, 255
 Transforming growth factor- β 1 (TGF- β 1), 475, 547–548
 Trichostatin A (TSA), 13
 Trithorax proteins, 187, 253. *See also* Polycomb group proteins (PcGs)
 Trypan blue, 20
 Tumor-initiating cells (TICs), 427
 Tumor stem cells, 372–373
 Tumor suppression genes (TSGs)
 background to research, 565–566
 cellular senescence and (*see* Cellular senescence)
 defined, 565
 evolutionary scenarios of, 567
 evolution of in *Drosophila*, 567–568
 evolution of in vertebrates, 568–569
 mouse models for astrocytomas, 422–423
 pathways and astrocytomas, 422
 planarians and choanoflagellates and, 567
 study conclusions, 570–571
 types of with regard to life span, 566–567
 Type B cell generation of interneurons, 358–360

U

Unpaired (Upd), 138–139
 Urodele limb regeneration. *See* Limb regeneration

V

Ventricular zone (VZ), 358. *See also* Notch pathway and signaling
 Vitamin D receptor (VDR), 508

W

Wnt/ β -catenin signaling
 epidermal stem cells and, 504–505
 in epithelial skin cells, 338
 Islet-1 cardiovascular progenitors, 300, 302
 and lung cancer stem cells, 486
 and the mammary gland, 474
 Wnt signaling/pathway
 biochemical properties of Wnt proteins, 60–61
 embryonic stem cells and, 63
 pathway described, 59–60
 research involving stem cells, 63–64
 stem cell control and, 63
 study conclusions, 64
 transcriptional regulatory circuitry in ES cells and, 187–188
 in transcriptional regulatory networks, 205
 Wnts as morphogens, 62–63
 Wnt secretion, 61–62
 WUS-CLV feedback loop, 244–245

X

Xenopus
 embryogenesis (*see* Reprogramming and differentiation in mammals)
 Wnt signaling and, 120

Y

Yeast
 asymmetric cell division in
 asymmetric segregation of kinetochore proteins, 82–84
 asymmetry of spindle pole body segregation, 84
 histone *HTA1* segregation, 82
 lack of evidence of immortal strands in yeast, 86–87
 segregating immortal DNA

strands, 84–85
 selective centromere segregation, 87
 study conclusions, 87
 study overview, 81
 testing the immortal strand hypothesis, 85–86
 tracking nonencoded protein, 82
 epigenetic inheritance and reprogramming in heterochromatin and the cell cycle in yeast, 266
 heterochromatin regulation in plants, 266–267
 reprogramming and cancer, 269–270
 RNAi mechanism in fission yeast, 265–266
 small RNA-mediated transposon control, 269
 study conclusions, 270
 heterochromatic silencing in epigenetic reprogramming and plant germ cells, 267–269
 heterochromatin and the cell cycle in yeast, 266
 heterochromatin regulation in plants, 266–267
 reprogramming and cancer, 269–270
 RNAi mechanism in fission yeast, 265–266
 small RNA-mediated transposon control, 269
 study conclusions, 270

Z

Zebra fish (*Danio rerio*)
 advantages of model system, 115
 embryogenesis, 33–34
 embryonic hematopoiesis, 111–112
 migratory routes of HSCs, 114–115
 origin of blood cells, 112
 signal transduction pathways in HSC induction, 114
 study conclusions, 115–116
 transcriptional regulators of HSC formation, 112–114
 Zygotic genome activation (ZGA)
 defined, 90–91
 mechanism, 95–96
 timing, 93–95

Cold Spring Harbor Symposia on Quantitative Biology

Subject Index

Cold Spring Harb Symp Quant Biol 2008 73: 603-612
Access the most recent version at doi:[10.1101/s73/index](https://doi.org/10.1101/s73/index)

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to:
<http://symposium.cshlp.org/subscriptions>